• Otsuka Pharmaceutical Co. Ltd., of Tokyo, said the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-6 not to approve tolvaptan for the treatment of autosomal dominant polycystic kidney disease. The FDA is not bound by the committee's guidance but takes its advice into consideration.